James H Mackaness's most recent trade in Soleno Therapeutics Inc was a trade of 36,157 Common Stock done at an average price of $70.0 . Disclosure was reported to the exchange on March 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 70.03 per share. | 27 Mar 2025 | 36,157 | 113,220 (0%) | 0% | 70.0 | 2,531,919 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 69.07 per share. | 27 Mar 2025 | 25,799 | 149,377 (0%) | 0% | 69.1 | 1,782,022 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.25 per share. | 27 Mar 2025 | 20,000 | 175,176 (0%) | 0% | 5.3 | 105,000 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 20,000 | 0 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.75 per share. | 27 Mar 2025 | 20,000 | 125,176 (0%) | 0% | 30.8 | 615,000 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 20,000 | 67,251 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.41 per share. | 27 Mar 2025 | 15,000 | 155,176 (0%) | 0% | 2.4 | 36,150 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 15,000 | 15,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 10,000 | 3,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.10 per share. | 27 Mar 2025 | 10,000 | 135,176 (0%) | 0% | 5.1 | 51,000 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 70.80 per share. | 27 Mar 2025 | 8,044 | 105,176 (0%) | 0% | 70.8 | 569,494 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 68.79 per share. | 27 Mar 2025 | 6,498 | 109,974 (0%) | 0% | 68.8 | 446,985 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 5,000 | 0 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 27 Mar 2025 | 5,000 | 140,176 (0%) | 0% | 2.6 | 12,975 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 67.70 per share. | 27 Mar 2025 | 4,940 | 116,472 (0%) | 0% | 67.7 | 334,441 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 69.84 per share. | 27 Mar 2025 | 3,762 | 106,212 (0%) | 0% | 69.8 | 262,727 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 66.79 per share. | 27 Mar 2025 | 2,717 | 121,412 (0%) | 0% | 66.8 | 181,473 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 65.97 per share. | 27 Mar 2025 | 1,669 | 124,129 (0%) | 0% | 66.0 | 110,102 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 71.74 per share. | 27 Mar 2025 | 563 | 105,262 (0%) | 0% | 71.7 | 40,391 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 70.73 per share. | 27 Mar 2025 | 387 | 105,825 (0%) | 0% | 70.7 | 27,374 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 72.64 per share. | 27 Mar 2025 | 86 | 105,176 (0%) | 0% | 72.6 | 6,247 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 31,000 | 31,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2025 | 14,500 | 125,798 (0%) | 0% | 0 | Common Stock | |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 46.18 per share. | 02 Jan 2025 | 3,791 | 111,298 (0%) | 0% | 46.2 | 175,055 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.37 per share. | 02 Jan 2025 | 3,762 | 115,410 (0%) | 0% | 45.4 | 170,665 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.92 per share. | 02 Jan 2025 | 321 | 115,089 (0%) | 0% | 45.9 | 14,740 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 49.34 per share. | 01 Oct 2024 | 7,248 | 120,001 (0%) | 0% | 49.3 | 357,586 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 50.25 per share. | 01 Oct 2024 | 829 | 119,172 (0%) | 0% | 50.2 | 41,656 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 47.16 per share. | 28 Aug 2024 | 5,595 | 128,524 (0%) | 0% | 47.2 | 263,858 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 47.19 per share. | 28 Aug 2024 | 3,561 | 137,219 (0%) | 0% | 47.2 | 168,053 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 48.03 per share. | 28 Aug 2024 | 3,100 | 134,119 (0%) | 0% | 48.0 | 148,885 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 47.83 per share. | 28 Aug 2024 | 1,275 | 127,249 (0%) | 0% | 47.8 | 60,987 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.89 per share. | 05 Aug 2024 | 4,636 | 140,780 (0%) | 0% | 45.9 | 212,746 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.48 per share. | 05 Aug 2024 | 3,858 | 151,905 (0%) | 0% | 45.5 | 175,449 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 46.14 per share. | 05 Aug 2024 | 2,991 | 148,914 (0%) | 0% | 46.1 | 138,016 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 05 Aug 2024 | 2,699 | 145,416 (0%) | 0% | 45.2 | 122,122 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 43.64 per share. | 05 Aug 2024 | 799 | 148,115 (0%) | 0% | 43.6 | 34,868 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 100,000 | 155,763 (0%) | 0% | 0 | Common Stock | |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 41.63 per share. | 01 Jul 2024 | 5,622 | 55,763 (0%) | 0% | 41.6 | 234,018 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 41.22 per share. | 01 Jul 2024 | 1,568 | 61,385 (0%) | 0% | 41.2 | 64,636 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 41.12 per share. | 01 Apr 2024 | 3,104 | 65,024 (0%) | 0% | 41.1 | 127,645 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 41.67 per share. | 01 Apr 2024 | 2,071 | 62,953 (0%) | 0% | 41.7 | 86,293 | Common Stock |
| Soleno Therapeutics Inc | H. Mackaness James | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 56,000 | 68,128 (0%) | 0% | 0 | Common Stock | |
| Soleno Therapeutics Inc | H. James Mackaness | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 37,000 | 37,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | Mackaness H. James | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 15,000 | 5,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | Mackaness James H. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.60 per share. | 11 Dec 2023 | 15,000 | 44,610 (0%) | 0% | 2.6 | 38,925 | Common Stock |
| Soleno Therapeutics Inc | H. James Mackaness | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 37.06 per share. | 11 Dec 2023 | 13,849 | 12,128 (0%) | 0% | 37.1 | 513,306 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.16 per share. | 11 Dec 2023 | 12,381 | 25,977 (0%) | 0% | 36.2 | 447,656 | Common Stock |
| Soleno Therapeutics Inc | Mackaness H. James | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.49 per share. | 11 Dec 2023 | 6,252 | 38,358 (0%) | 0% | 35.5 | 221,866 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.65 per share. | 30 Nov 2023 | 4,186 | 21,303 (0%) | 0% | 28.7 | 119,937 | Common Stock |
| Soleno Therapeutics Inc | H. James Mackaness | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2023 | 3,500 | 0 | - | - | Warrants (right to buy) | |
| Soleno Therapeutics Inc | Mackaness James H. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 02 Oct 2023 | 3,500 | 41,879 (0%) | 0% | 2.5 | 8,750 | Common Stock |
| Soleno Therapeutics Inc | James Mackaness H. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.50 per share. | 02 Oct 2023 | 2,666 | 36,236 (0%) | 0% | 4.5 | 11,997 | Common Stock |
| Soleno Therapeutics Inc | James Mackaness H. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2023 | 2,666 | 0 | - | - | Warrants (right to buy) | |
| Soleno Therapeutics Inc | Mackaness James H. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Oct 2023 | 2,143 | 0 | - | - | Warrants (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.75 per share. | 02 Oct 2023 | 2,143 | 38,379 (0%) | 0% | 1.7 | 3,750 | Common Stock |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 87,251 | 87,251 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 29,084 | 33,570 (0%) | 0% | 0 | Common Stock | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2023 | 3,500 | 3,500 | - | - | Warrants (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2023 | 2,143 | 2,143 | - | - | Warrants (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 30,000 | 30,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2022 | 300,000 | 300,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 Mar 2022 | 40,000 | 67,295 (0%) | 0% | - | Common Stock | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 Mar 2022 | 40,000 | 40,000 | - | - | Warrant (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2022 | 195,000 | 195,000 | - | - | Employee stock option (right to buy) | |
| Soleno Therapeutics Inc | James H. Mackaness | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.89 per share. | 13 Sep 2021 | 11,235 | 27,295 (0%) | 0% | 0.9 | 9,981 | Common Stock |